Characteristics of AML patients in this study
| . | No. . |
|---|---|
| No. | 36 |
| Median age, y (range) | 55 (17-81) |
| FAB type | |
| M0 | 1 |
| M1 | 11 |
| M2 | 7 |
| M3 | 0 |
| M4 | 13 |
| M5 | 2 |
| M6 | 2 |
| Prognostic group | |
| Favorable | 10 |
| Intermediate | 23 |
| Adverse | 3 |
| Response to first-line therapy | |
| Complete remission | 26 |
| Induction failure | 4 |
| Death not from leukemia | 6 |
| Relapse | 10 |
| . | No. . |
|---|---|
| No. | 36 |
| Median age, y (range) | 55 (17-81) |
| FAB type | |
| M0 | 1 |
| M1 | 11 |
| M2 | 7 |
| M3 | 0 |
| M4 | 13 |
| M5 | 2 |
| M6 | 2 |
| Prognostic group | |
| Favorable | 10 |
| Intermediate | 23 |
| Adverse | 3 |
| Response to first-line therapy | |
| Complete remission | 26 |
| Induction failure | 4 |
| Death not from leukemia | 6 |
| Relapse | 10 |
AML indicates acute myeloid leukemia; and FAB, French-American-British.